Skip to main content

Journey Medical Corp

corporate_fare Company Profile

Journey Medical Corp

DERM·NASDAQ·Life Sciences·CIK 0001867066

Journey Medical Corporation is a commercial-stage pharmaceutical company focused on selling and marketing U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for dermatological conditions. The company's current portfolio includes eight FDA-approved prescription drugs for dermatological conditions, all marketed in the U.S. Journey Medical Corporation acquires product rights and candidates by licensing or acquiring ownership interests, funding research and development, and then commercializing these products through its field sales organization. It operates as a controlled subsidiary of Fortress Biotech, Inc. On November 1, 2024, the FDA approved Emrosi for treating inflammatory lesions of rosacea in adults. Emrosi was developed in collaboration with Dr. Reddy's Laboratories, Ltd. Initial supply of Emrosi became available in March 2025, and sales promotion began in April 2025. Journey Medical Corporation is commercializing Emrosi in the U.S. using its existing commercial team. Effective after the close of U.S. equity markets on June 27, 2025, the company joined the small cap Russell 2000® Index and the broad-market Russell 3000® Index as part of the 2025 annual Russell Index reconstitution. Journey Medical Corporation was incorporated in Delaware in 2014.

Journey Medical Corp (NASDAQ:DERM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 13 items for DERM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 13 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for DERM spans 10-Q, 8-K, 10-K, 424B3.

Recent high-impact activity:

  • Journey Medical 10-Q: Q3 Revenue $19.0M, Going-Concern Doubt Persists
  • Journey Medical Q3 Revenue Rises 8% as Emrosi Sales Jump 84%
  • Journey Medical Q2 Revenue Up 23%, But Going Concern Warning Persists
  • Journey Medical Q2 Revenue Jumps 23%, Loss Narrows to $0.3M
  • Journey Medical Q2 Revenue Up 23% to $18.5M, Loss Narrows to $0.3M

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$61.86M
Net Income
-$11.43M
Diluted EPS
-$0.47
Op. Cash Flow
-$12.44M
Gross Profit
$40.93M
Operating Income
-$8.17M
Cash & Equivalents
$24.09M
Total Debt
$25.28M
Debt / Equity
0.79×
Net Margin
-18.5%
Shares Outstanding
24.5M sh
Source: 10-K · filed 2026-03-25 · accession 0001104659-26-034629

Short Interest & Short Volume

15.07 days to cover

FINRA reported short interest of 3,085,027 shares in DERM as of the October 30, 2026 settlement, a 3.3% increase from the prior period — about 15.1 days to cover at its recent average daily volume. On November 20, 2026, 37.2% of DERM volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,085,027 shares as of October 30, 2026
Change vs prior period▲ 3.3%
Days to cover15.07 at avg daily volume of 204,724
Daily short volume (FINRA facilities)37.2% of 96,483 shares on November 20, 2026
5-day average short volume34.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with D →
$3.3
52-week range · as of 2026-11-12 $3.3 – $9.55
Market cap
$93.16M
Volume
244.7K (1.1× avg)
3-mo avg 222K
Live data · 2026-11-21 05:40 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed DERM - Latest Insights

DERM
Nov 12, 2026, 4:35 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.90
Real-time Price: $3.30 info
Change: -$1.60 (-33%) info
Market Cap: $93.161M info
DERM
Nov 12, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.35
Real-time Price: $3.30 info
Change: -$1.05 (-24%) info
Market Cap: $93.161M info
DERM
Aug 12, 2026, 4:40 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.99
Real-time Price: $3.30 info
Change: -$3.69 (-53%) info
Market Cap: $93.161M info
DERM
Aug 12, 2026, 4:11 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $6.61
Real-time Price: $3.30 info
Change: -$3.31 (-50%) info
Market Cap: $93.161M info
DERM
Aug 12, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.61
Real-time Price: $3.30 info
Change: -$3.31 (-50%) info
Market Cap: $93.161M info
DERM
May 13, 2026, 4:33 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.57
Real-time Price: $3.30 info
Change: -$2.27 (-41%) info
Market Cap: $93.161M info
DERM
May 13, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.50
Real-time Price: $3.30 info
Change: -$2.20 (-40%) info
Market Cap: $93.161M info
DERM
Apr 21, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.31
Real-time Price: $3.30 info
Change: -$2.01 (-38%) info
Market Cap: $93.161M info
DERM
Mar 25, 2026, 6:09 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $6.28
Real-time Price: $3.30 info
Change: -$2.98 (-47%) info
Market Cap: $93.161M info
DERM
Mar 25, 2026, 5:35 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $6.35
Real-time Price: $3.30 info
Change: -$3.05 (-48%) info
Market Cap: $93.161M info
DERM
Mar 25, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.83
Real-time Price: $3.30 info
Change: -$3.53 (-52%) info
Market Cap: $93.161M info
DERM
Jan 23, 2026, 4:06 PM EST
Filing Type: 424B3
Importance Score:
8
Price at Filing: $8.68
Real-time Price: $3.30 info
Change: -$5.38 (-62%) info
Market Cap: $93.161M info
DERM
Jan 15, 2026, 4:43 PM EST
Filing Type: S-3
Importance Score:
9
Price at Filing: $8.01
Real-time Price: $3.30 info
Change: -$4.71 (-59%) info
Market Cap: $93.161M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets